shares of eqrx inc fell 34 to 359 in early trading thursday after it suspended development of one of its cancer drugs in the us the cambridge massbased pharmaceutical company said it would discontinue development of sugemalimab for use in chemotherapy treatment of stage iv nonsmall cell lung cancer the us food and drug administration said it would require a second phase 3 trial for the sugemalimabchemotherapy combination after results of a first phase 3 trial failed to support a pathway to approval the company said eqrx said it remains in discussions with the fda to approve treatment of extranodal nktcell lymphoma with sugemalimab plus chemotherapy the company said it would prioritize and adopt marketbased pricing for aumolertinib and lerociclib drugs it has indicated may have the potential to treat lung breast and other cancers